Copper-Transporting ATPases and Menkes Disease in Practice

Menkes disease is a rare X-linked disorder caused by pathogenic variants in ATP7A, which encodes a copper-transporting ATPase. Defective copper handling disrupts copper-dependent enzymes in the developing nervous system and other organs. The result is a severe multisystem condition in which early diagnosis and treatment can radically alter the course. Learn more about ストレッチングの種類と急性効果.

The 16th International Symposium on Applied Bioinorganic Chemistry in Ioannina, Greece, in June 2023, brought together researchers in inorganic chemistry, molecular biology and clinical translation. Organised by the University of Ioannina, ISABC 2023 created a fitting forum for exchanging evidence on copper transporters, metal homeostasis, diagnostics and therapeutics.

For Australian audiences, the topic reaches into newborn screening, specialist referral, therapeutic-goods regulation and research networks linking cities such as Sydney, Melbourne, Brisbane and Perth. Understanding the molecular defect is only one part of improving outcomes; timely diagnosis, equitable treatment and sustained laboratory collaboration determine whether scientific progress reaches families.

Clinical foundations of a copper transport disorder

ATP7A is a P-type ATPase that moves copper using energy from ATP. It normally helps deliver copper to enzymes in the trans-Golgi network and, when cellular copper rises, relocates to the plasma membrane to export excess copper. Loss of ATP7A function also impairs intestinal copper uptake, leaving little copper available for circulation and tissue use.

Clinically, affected boys may initially appear healthy, then develop poor feeding, weakness, seizures, developmental regression and failure to thrive. Sparse, pale or kinky hair can suggest abnormal pigmentation, while vascular tortuosity and skeletal or connective-tissue abnormalities reflect wider multisystem effects. A low serum copper concentration alone is insufficient, because inflammation and malnutrition can produce similar results.

ATP7A, ATP7B and copper handling

ATP7B performs a related but distinct role. In hepatocytes, it supports copper incorporation into apoproteins and exports surplus copper into bile; pathogenic ATP7B variants cause Wilson disease rather than Menkes disease. This distinction matters when interpreting liver copper, neurological phenotypes and family testing, yet both proteins show how membrane trafficking can protect cells from toxic copper while ensuring enough reaches catalytic sites.

Cells regulate copper through import, storage, export and incorporation into cuproenzymes such as cytochrome c oxidase, superoxide dismutase, tyrosinase and dopamine beta-hydroxylase. ATP7A acts within a wider system: copper chaperones, metallothionein, Golgi processing and lysosomal transport all influence the availability of this metal.

Research models must represent human biology accurately. Patient-derived cells can expose ATP7A trafficking defects; organoids and induced pluripotent stem cells can test developmental consequences; and animal models remain valuable for systemic copper distribution. Each approach has limitations, so findings should be triangulated across chemistry, genetics and clinical observation.

From suspicion to treatment

Suspicion usually begins with the clinical pattern, low serum copper and low ceruloplasmin, followed by molecular confirmation of an ATP7A variant. Testing affected relatives can distinguish a de novo pathogenic variant from an inherited one and guide counselling. Prenatal and preimplantation testing may be possible when a familial variant is known, subject to local law and specialist review.

The principal disease-directed therapy is parenteral copper histidinate, which supplies copper that cannot be absorbed normally through the gut. Its benefit is greatest when started very early, before irreversible neurological injury develops, and access depends on specialist assessment, regulatory pathways and sustained parenteral treatment. Supportive care remains essential for seizures, feeding, nutrition, development and family support.

Research priorities include sensitive early biomarkers, improved delivery of copper to the brain, tolerable dosing and international outcome registries. Newborn screening panels vary across Australian states and territories, and Menkes disease is not detected uniformly. Prospective pathways should connect laboratory flags to urgent paediatric assessment rather than wait for a specialist to reinterpret a borderline copper result.

Australian clinical and research realities

Australian families commonly enter care through a public maternity hospital, a general practitioner and a paediatric service, with definitive assessment available through tertiary genetics and metabolic teams in major centres. Telehealth can support regional families, but treatment, genetic counselling and monitoring may still require travel. Clear referral routes for hypotonia, seizures and abnormal copper results can shorten the path to diagnosis.

The Australian market includes prescription medicines, compounded preparations and listed complementary products, each governed by different pathways. Many consumers encounter copper-containing supplements through pharmacies and online marketplaces, so clinicians may need to ask about self-selected products alongside prescribed therapy. The Therapeutic Goods Administration oversees therapeutic goods and advertising, while the Pharmaceutical Benefits Scheme determines subsidised access. For an unapproved copper formulation, the TGA Special Access Scheme may be relevant.

Clinical research in Australia operates under the NHMRC National Statement, institutional human research ethics approval and applicable state and territory law; the Privacy Act 1988 governs many uses of personal health information. Indigenous data governance also requires respect for Aboriginal and Torres Strait Islander research priorities. These requirements can protect participants and build trust in rare-disease studies that involve genetic information.

Conference travel adds another layer, especially for researchers moving between Australian cities. Poster sessions can involve long periods of standing, so a review of acute stretching effects may help delegates choose brief recovery options, alongside hydration and individual movement advice.

ISABC 2023 and paths for collaboration

ISABC 2023 provided a useful bridge between molecular discovery and clinical need. Its programme covered applied bioinorganic chemistry, while young scientist travel awards, scholarships and poster prizes supported researchers facing financial barriers. For Australia, the symposium could strengthen links among universities, hospitals, patient organisations and overseas laboratories working on copper biology.

Delegates preparing a travel award application should review the travel grant application guidance early, checking eligibility, documents, timing and presentation before submission. The same discipline applies to abstracts and posters, where a clear pathway from ATP7A biology to patient outcomes helps reviewers see novelty and practical relevance. A direct comparison of ATP7A- and ATP7B-associated disease clarifies the distinct clinical priorities that collaborations must address.

Feature	ATP7A-associated Menkes disease	ATP7B-associated Wilson disease
Gene location	ATP7A on the X chromosome	ATP7B on chromosome 13
Main cellular role	Golgi delivery and membrane export of copper	Hepatic export and biliary copper handling
Inheritance	X-linked recessive	Autosomal recessive
Typical pattern	Neurodegeneration, growth failure, pigmentation and vascular changes	Hepatic and neurological disease, sometimes haemolysis
Key diagnostic focus	ATP7A sequencing and copper studies	ATP7B sequencing, ceruloplasmin and liver copper assessment
Core care challenge	Urgent copper replacement and neurological support	Copper removal, liver care and lifelong monitoring

Researchers can act by reviewing the symposium resources, checking participation and award requirements, and contacting the official secretariat. The University of Ioannina’s ISABC platform remains the central source for programme information and archived materials, while Zita Congress & Event Management handles registration, accommodation and abstract-related enquiries.

Australian delegates should coordinate institutional approvals early, budget for international travel and clinical research requirements, and approach poster or travel-award applications as part of a sustained international collaboration on metal-transport disorders.